Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

BMH Inc

Neither a doctor nor a teaching hospital

Research payments

$3,031,885

226 payments

Through program year 2025, BMH Inc is reported as receiving $3,031,885 in research payments, across 226 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $296,857 44
2024 Research $579,316 18
2023 Research $572,548 72
2022 Research $986,374 49
2021 Research $582,945 41
2020 Research $13,846 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Pfizer Inc. $1,415,748 96 payments
  2. Moderna TX, Inc. $883,698 61 payments
  3. Bavarian Nordic A/S $718,593 67 payments
  4. Ethicon Inc. $13,846 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,285,747 57 payments
  2. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $411,477 3 payments
  3. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $396,428 44 payments
  4. Nct05238025 $322,165 23 payments
  5. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $251,654 15 payments
  6. A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age $175,302 12 payments
  7. A Phase 23 Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Sarscov2 Rna Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Pregnant Women 18 Years of Age and Older $75,594 22 payments
  8. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers $45,202 29 payments
  9. An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $32,771 11 payments
  10. A Phase 2B Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women 18 Through 49 Years of Age and Their Infants $21,637 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record